Tag: Dr. Nazli Azimi

Bioniz Therapeutics announces positive data from BNZ-1 phase 1/2 trial in rCTCL

pharmanewsdaily- December 6, 2020

Bioniz Therapeutics has announced positive data from a phase 1/2 clinical trial of BNZ-1 for the treatment of relapsed or refractory cutaneous T-cell lymphoma (rCTCL). ... Read More